Last reviewed · How we verify
Lidocaine, perineural injection, intraoperatively
Lidocaine, administered as a perineural injection intraoperatively by Harran University, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the extended patent protection, which helps maintain its competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Lidocaine, perineural injection, intraoperatively |
|---|---|
| Also known as | lidocaine |
| Sponsor | Harran University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: